A single-site study of the effectiveness of Dapagliflozin for diabetic patients admitted to the intensive care unit

INTERVENTION: Once daily oral administration of 10mg Dapagliflozin for a maximum of 28 days from the time of enrolment while the participant is admitted to the intensive care unit with adherence of study intervention via audit of hospital medication charts. CONDITION: Diabetes; ; Diabetes Metabolic and Endocrine ‐ Diabetes PRIMARY OUTCOME: Composite outcome of the time‐course and magnitude of blood glucose level change.[From the time of enrolment until discharge from the intensive care unit obtained via medical record review.] SECONDARY OUTCOME: Incidence of hypoglycaemia defined as a blood glucose level of less than 4 mmol/L.[From the time of enrolment until discharge from the intensive care unit as documented in the patient's medical record.] Mortality at hospital discharge[Mortality status at the time of hospital discharged as documented in the patient's medical record.] Mortality at intensive care unit discharge[Mortality status at the time of intensive care unit discharged as documented in the patient's medical record.] Total dose of insulin given while admitted to intensive care.[Accumulative dose in international units of insulin administered from randomisation until discharge from the ICU or 28‐days whichever comes first, as documented in the patient's medical record.] INCLUSION CRITERIA: Adult aged 18 years or greater Expected to be admitted to the ICU until the day after tomorrow Pre‐existing diagnosis of Type‐2 diabetes mellitus Estimated Glomerular Filtration rate (eGFR) of less than 45 ml/min/1.73m2 Able to take medication enterically